Pazopanib induced a partial response in a patient with metastatic fibrosarcomatous dermatofibrosarcoma protuberans without genetic translocations resistant to mesna, doxorubicin, ifosfamide and dacarbazine chemotherapy and gemcitabine-docetaxel chemotherapy

J Dermatol. 2017 Mar;44(3):e21-e22. doi: 10.1111/1346-8138.13717. Epub 2016 Dec 18.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Abdomen
  • Angiogenesis Inhibitors / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols
  • Dacarbazine
  • Deoxycytidine / analogs & derivatives
  • Dermatofibrosarcoma / diagnosis*
  • Dermatofibrosarcoma / drug therapy*
  • Dermatofibrosarcoma / surgery
  • Docetaxel
  • Doxorubicin
  • Drug Resistance, Neoplasm
  • Fatal Outcome
  • Gemcitabine
  • Humans
  • Ifosfamide
  • Indazoles
  • Male
  • Mesna
  • Middle Aged
  • Pyrimidines / therapeutic use*
  • Skin Neoplasms / diagnosis*
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / surgery
  • Sulfonamides / therapeutic use*

Substances

  • Angiogenesis Inhibitors
  • Indazoles
  • Pyrimidines
  • Sulfonamides
  • Deoxycytidine
  • Docetaxel
  • Dacarbazine
  • pazopanib
  • Doxorubicin
  • Mesna
  • Ifosfamide
  • Gemcitabine